发现长效APOC3siRNA用于治疗高甘油三血症患者
Thazha P Prakash1, Adam E Mullick1, Stan Riney1
1Ionis Pharmaceuticals Inc., 2855 Gazelle Ct., Carlsbad CA 92010, United States.
Nucleic acids research
|October 30, 2025
概括
研究人员开发了一种新的,长效的阿波利波蛋白C-III (APOC3) siRNA疗法. 这种向RNA治疗显示出有效管理高甘油三血症和降低心血管疾病风险的潜力,通过提高安全性和更少的剂量频率.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 脂蛋白C-III (APOC3) 是甘油三代谢的组成部分;高水平会导致过高甘油三,增加心血管疾病和胰腺炎的风险.
- 功能丧失的APOC3变体与降低的甘油三和冠状动脉疾病相关.
- 由肝细胞产生的APOC3mRNA是RNA向治疗的关键标,如反感性寡核酸 (ASO) 和小干扰RNA (siRNA).
研究的目的:
- 系统地评估siRNA的化学修饰,并确定具有最小2'-F核酸的持久APOC3siRNA.
- 探索寡核酸支架的结构-活性关系 (SAR),以优化siRNA的功效,疗效和持续时间.
主要方法:
- 在各种寡核酸化学修饰支架上进行了广泛的结构-活性关系 (SAR) 研究.
- 在临床前模型中评估了不同siRNA设计的功效,疗效和耐用性.
- 在人类细胞,动物和非人类灵长类动物中评估了候选物的选择性和耐受性.
主要成果:
- 确定了一种新的APOC3向siRNA,具有独特的化学支架,在临床前研究中表现出强大的活性和延长的持续时间.
- 临床前评估显示,在多种物种中,安全性和耐受性表现出色.
- 对比分析表明,siRNA可能与临床阶段药物具有相似或更高的效率和疗效,并且可能不太频繁地使用.
结论:
- 一种新的,化学修饰的APOC3siRNA已经开发出来,具有治疗高甘油三血症的巨大潜力.
- 鉴定的siRNA显示出有希望的耐用性,安全性和耐受性,这表明患者的治疗负担减少了.
- 这种RNA向疗法代表了管理高甘油三血症和相关心血管风险的潜在进展.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
311
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
311
01:24Lipid Absorption
2.4K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
2.4K
01:06Lipid Digestion
98.6K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
98.6K